To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients

Inclusion Criteria: * Patients who have completed the core study with no significant safety concerns Exclusion Criteria: * Diagnosis of other neurodegenerative disease and/or psychiatric disorders (with the exception of successfully treated depression). * Diagnosis or presence of an active, uncontrolled seizure disorder and/or cerebrovascular disease. * Diagnosis or presence of an active autoimmune and/or with an acute or chronic inflammation. Other protocol-defined inclusion/exclusion criteria may apply